Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 270

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)

Zhang, Hang, Xu, Haiwei, Ashby, Charles R., Assaraf, Yehuda G., Chen, Zhe‐Sheng, Liu, Hong‐Min·2021·Medicinal Research Reviews

Abstract

Multidrug resistance (MDR) remains one of the major impediments for efficacious cancer chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP‐binding cassette (ABC) transporter superfamily is considered one of the primary causes for cancer MDR, in which the role of P‐glycoprotein (P‐gp/ABCB1) has been most well‐established. The clinical co‐administration of P‐gp drug efflux inhibitors, in combination with anticancer drugs which are P‐gp transport substrates, was considered to be a treatment modality to surmount MDR in anticancer therapy by blocking P‐gp‐mediated multidrug efflux. Extensive attempts have been carried out to screen for sets of nontoxic, selective, and efficacious P‐gp efflux inhibitors. In this review, we highlight the recent achievements in drug design, characterization, structure–activity relationship (SAR) studies, and mechanisms of action of the newly synthetic, potent small molecules P‐gp inhibitors in the past 5 years. The development of P‐gp inhibitors will increase our knowledge of the mechanisms and functions of P‐gp‐mediated drug efflux which will benefit drug discovery and clinical cancer therapeutics where P‐gp transporter overexpression has been implicated in MDR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/med.21739

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 117 references

Research works printed but not linked: 47

  1. Seton‐Rogers S, 2016, Resistance: following different paths, Nat Rev Cancer, 16, 128, 10.1038/nrc.2016.23 · doi:10.1038/nrc.2016.23
  2. 10.1016/j.drup.2012.03.001 · doi:10.1016/j.drup.2012.03.001
  3. 10.1002/wcms.1316 · doi:10.1002/wcms.1316
  4. 10.1124/mol.58.3.624 · doi:10.1124/mol.58.3.624 · Paper page
  5. 10.1016/j.lfs.2018.10.048 · doi:10.1016/j.lfs.2018.10.048
  6. 10.2174/1381612822666160804093852 · doi:10.2174/1381612822666160804093852
  7. 10.1016/j.ejmech.2014.10.082 · doi:10.1016/j.ejmech.2014.10.082
  8. 10.1002/cmdc.201500538 · doi:10.1002/cmdc.201500538
  9. 10.1021/acs.jmedchem.6b00252 · doi:10.1021/acs.jmedchem.6b00252
  10. 10.1016/j.bmc.2016.04.055 · doi:10.1016/j.bmc.2016.04.055
  11. 10.1002/cmdc.201402463 · doi:10.1002/cmdc.201402463
  12. 10.1139/cjpp-2016-0518 · doi:10.1139/cjpp-2016-0518
  13. 10.1016/j.bmc.2016.03.065 · doi:10.1016/j.bmc.2016.03.065
  14. 10.1039/C6RA02405J · doi:10.1039/c6ra02405j
  15. 10.1016/j.bmc.2018.03.045 · doi:10.1016/j.bmc.2018.03.045
  16. 10.1111/cbdd.13338 · doi:10.1111/cbdd.13338
  17. 10.1016/j.bioorg.2019.01.039 · doi:10.1016/j.bioorg.2019.01.039
  18. 10.1021/jacs.6b11188 · doi:10.1021/jacs.6b11188
  19. 10.1021/acs.joc.8b00322 · doi:10.1021/acs.joc.8b00322
  20. 10.1021/acs.jmedchem.0c00337 · doi:10.1021/acs.jmedchem.0c00337
  21. 10.1016/j.ejmech.2018.04.012 · doi:10.1016/j.ejmech.2018.04.012
  22. 10.1080/14756366.2020.1747449 · doi:10.1080/14756366.2020.1747449
  23. 10.1016/j.ejmech.2018.01.092 · doi:10.1016/j.ejmech.2018.01.092
  24. 10.1021/jm9810194 · doi:10.1021/jm9810194
  25. 10.1021/jm050542x · doi:10.1021/jm050542x
  26. 10.1021/jm0614432 · doi:10.1021/jm0614432
  27. 10.1002/cmdc.201500143 · doi:10.1002/cmdc.201500143
  28. 10.1021/jm400930e · doi:10.1021/jm400930e
  29. 10.1016/j.bmc.2015.07.027 · doi:10.1016/j.bmc.2015.07.027
  30. 10.1016/j.ejmech.2016.09.070 · doi:10.1016/j.ejmech.2016.09.070
  31. Feng S‐L, 2020, Nobiletin potentiates paclitaxel anticancer efficacy in A549/T xenograft model: pharmacokinetic and pharmacological study, Phytomedicine, 67
  32. 10.1515/hc-2016-0034 · doi:10.1515/hc-2016-0034
  33. 10.1016/j.ejphar.2014.10.058 · doi:10.1016/j.ejphar.2014.10.058
  34. 10.1039/C4MD00506F · doi:10.1039/c4md00506f
  35. 10.1016/j.bmcl.2015.05.018 · doi:10.1016/j.bmcl.2015.05.018
  36. 10.1016/j.bmc.2015.05.016 · doi:10.1016/j.bmc.2015.05.016
  37. 10.1021/mp500770e · doi:10.1021/mp500770e
  38. 10.1016/j.ejmech.2016.08.044 · doi:10.1016/j.ejmech.2016.08.044
  39. 10.1016/j.ejmech.2014.10.044 · doi:10.1016/j.ejmech.2014.10.044
  40. 10.1021/acs.joc.7b02012 · doi:10.1021/acs.joc.7b02012
  41. 10.1016/j.ejmech.2018.01.019 · doi:10.1016/j.ejmech.2018.01.019
  42. 10.1039/C5RA19857G · doi:10.1039/c5ra19857g
  43. 10.1016/j.ymeth.2014.12.012 · doi:10.1016/j.ymeth.2014.12.012
  44. 10.3390/molecules24091661 · doi:10.3390/molecules24091661
  45. 10.1016/j.ejmech.2016.01.034 · doi:10.1016/j.ejmech.2016.01.034
  46. 10.1016/j.ijpharm.2016.02.022 · doi:10.1016/j.ijpharm.2016.02.022
  47. 10.1016/j.ijantimicag.2014.10.023 · doi:10.1016/j.ijantimicag.2014.10.023

Cited by

See all 270

Metadata

Authors
Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H.
Venue
Medicinal Research Reviews
Publisher
Wiley
Published
2020-10-12
Volume
41
Issue
1
Pages
525-555
ISSN
  • 0198-6325 (ISSN-L)
  • 1098-1128
OpenAlex
W3091980736
Cited by
270
References
117
FWCI
11.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp). https://app.cochat.ai/papers/10.1002/med.21739
The paper
Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H. (2021). Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp). Medicinal Research Reviews. https://doi.org/10.1002/med.21739

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.